Aventis, Baxter Renew Battle Over Hemophilia Drug

Law360, New York (October 18, 2006, 12:00 AM EDT) -- Aventis Pharma SA has refiled a lawsuit claiming Baxter Healthcare Corp. markets a drug that infringes its patent related to Factor VIII, the protein necessary to form blood clots.

In the suit, which was filed Monday in the U.S. District Court in Wilmington, Del., Aventis said that Baxter’s hemophilia drug Advate contained a stabilized solution with Factor VIII activity.

The patent was originally granted in 1996 to what, after many mergers, would become Aventis.

Eventually, it became known that Baxter, a subsidiary of Baxter International Inc.,...
To view the full article, register now.